Second quarter revenues rose 27% year-over-year to $496M, with adjusted EBITDA at $139.2M and strong growth in proprietary product sales. 2026 guidance was reaffirmed, and the Avadel acquisition drove significant balance sheet expansion and new product contributions.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.